<DOC>
	<DOCNO>NCT03053908</DOCNO>
	<brief_summary>Alzheimer 's disease ( AD ) common neurodegenerative disease characterize accumulation amyloid plaque neurofibrillary tangle . Current consensus AD pathological process begin decade clinical symptom occur . This long `` preclinical '' phase AD might first become detectable middle-age deposit hyperphosphorylated tau ( P-tau ) transentorhinal cortex subcortical nucleus locus coeruleus ( LC ) nucleus basalis Meynert . There strong preliminary evidence show cerebrospinal fluid ( CSF ) level orexin-A ( OxA ) associate increase P-tau ( r=.52 , p &lt; .01 ) total-tau ( T-tau ) ( r=.42 , p &lt; .01 ) cognitively normal old adult ( mean age : 69.6±8.6 year ) . This study pose onset tauopathy LC result regulation orexin receptor , lead homeostatic increase OxA production hypothalamus , result change core body temperature ( CBT ) sleep disruption cause neurodegeneration . This hypothesis test demonstrate increase CSF P-tau associate vivo tau PET uptake , tau bind LC associated increase CSF OxA ( Aim 1 ) ; second , analyze downstream consequence increase central nervous system ( CNS ) OxA sleep architecture CBT ( Aim 2 ) . To test hypothesis , 30 old adult ( age 55-75 ) balance sex , first perform full clinical evaluation MRI ( visit 1-2 ) . Subjects later undergo 7 day actigraphy follow nocturnal polysomnography ( NPSG ) 2 consecutive night ( N1-2 ) measure CBT ( visit 3-4 ) . A morning lumbar puncture ( LP ) perform N2 obtain CSF . Tau burden analyze PET-MR use 18F-THK5351 , perform 1-4 week LP ( visit 5 ) .</brief_summary>
	<brief_title>Orexin Tau Pathology Cognitively Normal Elderly</brief_title>
	<detailed_description>There potential identify : 1 ) association CSF P-tau vivo 18F-THK5351 uptake ; 2 ) mechanism tau pathology may contribute orexin dysfunction ; 3 ) evidence orexin dysfunction disrupts sleep CBT rhythm ; , 4 ) CNS orexin dysfunction new therapeutic target AD prevention .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Subjects within normal limit neurological psychiatric examination . All subject enrol Clinical Dementia Rating ( CDR ) =0 MMSE &gt; 27 . All subject minimum 12 year education . Among minority subject &gt; 80 % elderly individual come NYUADC meet criterion . ( The education restriction reduce performance variance cognitive test measure improve sensitivity detect pathology disease progression use robust norm available NYU . Given majority subject meet criterion consider major selection bias generalization limitation study ) . An informed family member lifepartner ( preferably bedpartner ) interview confirm reliability subject interview . History brain tumor , MRI evidence brain damage brain disease include significant trauma , hydrocephalus , seizure , mental retardation serious neurological disorder ( e.g . Parkinson 's disease movement disorder ) . Subjects Fazekas scale &gt; 2 excluded110 . Significant history alcoholism drug abuse . History psychiatric illness ( e.g. , schizophrenia , bipolar , PTSD , lifelong history major depression ) . Geriatric Depression Scale ( short form ) &gt; 5 . Insulin dependent diabetes . Evidence clinically relevant cardiac , pulmonary , endocrine hematological condition . Physical impairment severity adversely affect validity psychological testing . Any prosthetic device ( e.g. , pacemaker surgical clip ) constitute hazard MRI image CBT measurement . History firstdegree family member early onset ( age &lt; 60 year ) dementia . Irregular sleepwake rhythm ( base actigraphy recording ) significant OSA ( AHI4 % ≥15 ) . Medications affect cognition sleep .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Orexin</keyword>
	<keyword>Cognitive Behavioral Therapy ( CBT )</keyword>
</DOC>